TargetBeta
ITK
IL2 inducible T cell kinase · also EMT, PSCTK2, LYK · Pleckstrin homology domain containing
2 programs in company-led studies act on ITK, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ritlecitinibrule | Pfizer | phase 3 | 428 running | BMX, BTK, JAK3, TEC, TXK | ChEMBL |
| soquelitinibrule | Corvus Pharmaceuticals | phase 3 | 54 running | – | NCIt |
Conditions their studies are in
- Hidradenitis Suppurativa, 2 programs
- Alopecia Areata, 1 program
- Arthritis, Rheumatoid, 1 program
- Chronic Urticaria, 1 program
- Dermatitis, Atopic, 1 program
- Lymphoma, T-Cell, 1 program
- Vitiligo, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2, 2026ritlecitinib · Pfizer · phase 3 · NCT07029711
- Dec 30, 2026soquelitinib · Corvus Pharmaceuticals · phase 3 · NCT03952078
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.